As we plunge into the abyss, here's a list of partnerships, collaborations and licenses I could find, some of which I had forgotten about. I've included any pertinent financial details, if possible. Does anyone know what happened with the earlier agreements? Many seem to be dead in the water. Ah, what could have been...
Here are Advaxis collaborations and licensing agreements that I know of. Some of whom, I have no idea if they're stll active:
Amgen: "Under the terms of the agreement, Amgen receives exclusive worldwide rights to develop and commercialize ADXS-NEO. Amgen will make an upfront payment to Advaxis of $40 million and purchase $25 million of Advaxis common stock. Amgen will be fully responsible for funding clinical and commercial activities. Advaxis will lead the clinical development of ADXS-NEO through proof-of-concept, retain manufacturing responsibilities, and receive development, regulatory and sales milestone payments of up to $475 million and potential high single digit to mid-double digit royalty payments based on worldwide sales"
Aratana: "Under the agreement, Aratana made a one-time upfront payment to Advaxis of $1 million and an additional $1.5 million equity investment in Advaxis common stock and warrants. Aratana agreed to pay up to an additional $6 million in clinical and regulatory milestones for each of the four products, assuming approvals in both cats and dogs in both United States and the European Union. In addition, Aratana agreed to pay up to $28.5 million in commercial milestones. Upon regulatory approval and commercialization of the immunotherapies, Aratana agreed to pay Advaxis a tiered royalty ranging from mid-single digit to 10% on net sales."
AstraZeneca: "As part of the agreement, Advaxis will fund and lead the clinical trials to assess the efficacy and safety of the combination. MedImmune holds a non-exclusive relationship with the company regarding HPV-driven tumors types. MedImune will have the first right of negotiation for further development of the combination therapy. Results from the study will guide decisions for the combination therapy’s potential for future clinical development."
Biocon: "Under the accord, financial terms of which were not revealed, Biocon will also have access to Advaxis’ innovative and proprietary immunotherapy technology that can be leveraged for the development of other novel therapeutics for various unmet medical needs."
BMY: "Under the terms of the agreement, each party will bear their own internal costs and provide its immunotherapy agents. Advaxis will sponsor the study and pay third-party costs."
Especificos Stendhal SA de CV: "Under the terms of the Agreement, Stendhal will pay $10 million toward the expenses of AIM2CERV, a planned global Phase 3 clinical trial in women with high-risk, locally advanced cervical cancer. This payment covers a significant portion of the total planned study costs. Stendhal will also work with Advaxis to complete the clinical trial of axalimogene filolisbac in Mexico, Brazil, Colombia, and other investigational sites in Latin American countries. Additionally, Stendhal will manage the regulatory approval process, promotion, commercialization and market access for axalimogene filolisbac in these markets. Advaxis and Stendhal will share profits on a pre-determined basis."
FusionVax: "Advaxis has exclusively licensed its lead clinical-stage product candidate, ADXS-HPV, to FusionVax. Under the terms of the agreement, Advaxis will license the rights to ADXS-HPV for the Asia territory, exclusive of India, for all indications. In exchange, FusionVax will pay Advaxis an up-front payment, certain event-based financial milestones, an annual exclusive licensing fee, and an annual net sales royalty in countries with issued patents. In exchange for the up-front payment, Advaxis will provide FusionVax an equal amount of Advaxis common stock. FusionVax will be responsible for conducting clinical trials and pursuing commercialization of ADXS-HPV in Asia and, in exchange, Advaxis will pay FusionVax net sales annual royalty on ADXS-HPV in the U.S. of less than 1%. The companies will share all data generated from their respective clinical trials. Advaxis and FusionVax will work together over the next six months to enter into a definitive exclusive licensing agreement based upon these terms. FusionVax has agreed to place into escrow a portion of the first event-based milestone pending the execution of a definitive licensing agreement."
Global BioPharma: "As part of the agreement, Advaxis will exclusively license to GBP the rights to ADXS-HPV for Asia, Africa, and former USSR territory, exclusive of India and certain other countries. Advaxis will receive event-based financial milestones, an annual development fee, and annual net sales royalty payments from GBP. Additionally, as an upfront payment, GBP will make an investment in Advaxis by purchasing shares of the company’s stock at market price. An option to purchase additional shares at a 150% premium to the stock price will also be available to GBP on the effective date of the agreement. GBP will be responsible for all clinical development and commercialization costs in the GBP territory and pay the clinical trial costs for up to 150 patients with cervical cancer for enrollment in Advaxis’ U.S. and GBP’s Asia registrational programs for cervical cancer."
Knight Therapeutics Inc: "In connection with the licensing agreement, Knight is purchasing directly from Advaxis 359,454 shares at $13.91 per share, which represents a 7 percent premium to the price of Advaxis's common stock at market close on August 25, 2015. In addition, Sectoral Asset Management, a leading Canadian-based global healthcare investment advisor, is purchasing 1,437,815 shares at $13.91 per share directly from Advaxis on behalf of its clients. The combined gross proceeds to Advaxis from these direct investments is $25 million. Under the terms of the licensing agreement, Knight will be responsible for all commercial activities related to Advaxis current and future products, including axalimogene filolisbac, ADXS-PSA and ADXS-HER2, in Canada. Advaxis is eligible to receive double digit royalty as well as sales milestones."
Merck: "... company will bear most costs of the study, which is slated to begin in early 2015 and probably be conducted by a contract research organization. Merck will provide the pembrolizumab, an injectable monoclonal antibody, to be used in the trial."
OS Therapies: "Under the terms of the license agreement, OS Therapies, in collaboration with the Children’s Oncology Group (COG) [1] , will be responsible for the conduct and funding of a clinical study evaluating ADXS-HER2 in recurrent, completely resected osteosarcoma. Advaxis will receive an upfront payment, reimbursement for product supply and other support, clinical, regulatory, and sales-based milestone payments, and royalties on future product sales. Additional details of the financial terms have not been disclosed."
Sellas: " Advaxis will conduct all preclinical activities required for an IND filing, with Sellas agreeing to oversee all clinical development and commercial activities. In return for the license, Sellas has agreed to pay Advaxis up to $358 million tied to achieving development, regulatory, and commercial milestones. Should the cancer immunotherapy candidate receive regulatory approval, Sellas has agreed to pay Advaxis single-digit to low double-digit royalties based on worldwide net sales upon commercialization."
